Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy.

ABSTRACT:

Objective

To determine whether incident AIDS-defining Kaposi sarcoma or Pneumocystis jiroveci pneumonia (PJP) is associated with combination antiretroviral therapy (cART) initiation.

Design

Compare risk for Kaposi sarcoma and PJP by time on cART and CD4 reconstitution.

Methods

: In the FHDH-ANRS CO4 cohort (N = 66 369), Kaposi sarcoma (N = 1811) and PJP (N = 1718) incidence rates were computed by demographic and HIV strata. Crude and adjusted relative risk (RR) with 95% confidence intervals (CIs) following cART initiation were calculated by Poisson regression with untreated patients during 1996-2009 as reference. CD4 cell counts were compared by Wilcoxon rank sum tests.

Results

The risk of Kaposi sarcoma was very high during months 1-3 on cART (N = 160, RRCrude

SUBMITTER: Lacombe JM 

PROVIDER: S-EPMC3623279 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature